News

Oculis to Showcase Innovations at November Investor Events

Oculis to Showcase Innovations at November Investor Events

Oculis to Showcase Innovations at Upcoming Investor Conferences

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) is gearing up for significant investor conferences this November, wherein the company's management is excited to share updates on their innovative approaches in neuro-ophthalmology and ophthalmology.

Highlighting Breakthrough Developments

As the company transitions into a pivotal leader in eye care, Oculis is poised to unveil updates related to its late-stage product portfolio. The advancements primarily spotlight:

Privosegtor and the PIONEER Program

Oculis is thrilled to announce the advancement of Privosegtor within the PIONEER program, moving into registrational trials for conditions like acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION). This follows a highly positive engagement with the FDA, setting the stage for pivotal research.

OCS-01 in Diabetic Macular Edema Trials

Exciting topline results for the OCS-01 trials, aimed at treating diabetic macular edema, are anticipated by the second quarter of 2026. This ocular treatment could become a breakthrough in the management of this condition, impacting many lives positively.

Licaminlimab and Precision Medicine

Furthermore, Oculis is preparing to present data from the Licaminlimab trial, part of the PREDICT-1 program focused on dry eye disease (DED). This program is particularly exciting as it marks one of the first genotype-based initiatives aimed at delivering personalized treatment plans for patients.

Investor Conference Details

Oculis is set to feature prominently in several conferences this month:

Guggenheim Securities Healthcare Innovation Conference

Scheduled for November 10-12 in Boston, U.S., Oculis' CEO, Riad Sherif, M.D., will host a fireside chat on November 11 at 2:30 pm ET.

Stifel Healthcare Conference

Additionally, from November 11-13 in New York, Riad Sherif, M.D., will participate in a chat on November 12 at 2:00 pm ET, further discussing the company’s vision and progress.

LifeSci Capital and Sofinnova Partners Growth & Innovation Summit

On November 17 in London, Oculis management is anticipated to engage in one-on-one meetings to foster direct connections with potential investors.

ICR Healthcare Conference

Also on November 17 in London, Dr. Sherif will contribute to a panel discussion entitled ‘Brave New World,’ shedding light on transformative advancements in eye health.

Oculis will be accessible for individual meetings throughout these conferences, and potential investors are encouraged to reach out through their representatives for engagement opportunities.

About Oculis

Oculis is a pioneering biopharmaceutical firm focusing on neuro-ophthalmic conditions that require immediate attention and innovative solutions. Their late-stage clinical pipeline displays immense promise, featuring:

Core Product Candidates

Privosegtor: Targeting optic neuropathies, offering a fresh approach in the PIONEER program.

OCS-01: Aiming for first-line status in non-invasive treatment for diabetic macular edema.

Licaminlimab: A novel treatment under exploration with a strong emphasis on personalized medicine.

Headquartered in Switzerland with robust operations in the U.S. and Iceland, Oculis is backed by a seasoned management team whose mission resonates deeply: to improve eye health through breakthrough innovations.

Contact Information

Oculis Contact
Ms. Sylvia Cheung, CFO
Email: sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Email: oculis@icrhealthcare.com

Frequently Asked Questions

What is Oculis focused on?

Oculis specializes in developing innovative solutions for neuro-ophthalmology and ophthalmology, addressing unmet medical needs.

Who is the CEO of Oculis?

Dr. Riad Sherif serves as the CEO, leading the company's strategic initiatives and development programs.

When are the investor conferences taking place?

The conferences are scheduled for November 10-13 and November 17, across various locations in the U.S. and the U.K.

What key programs are being highlighted by Oculis?

Oculis highlights several key programs including Privosegtor, OCS-01, and Licaminlimab, each targeting significant ocular conditions.

How can investors engage with Oculis?

Investors can schedule one-on-one meetings with the Oculis management team during the conferences, reaching out through their representatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 40

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Long March Reflections: Lesson of Adaptation Endures

Updated Category News Views 11

Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...

Continue Reading
Firehawk Defense Secures $150M, Valuation Hits $1.4B

Updated Category News Views 36

Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...

Continue Reading
Vertiv's Explosive Q3 Growth: A 2026 Power Move

Updated Category News Views 30

Vertiv's Third Quarter Triumph Imagine a company blowing past expectations like a hot knife through butter—yeah, that's Vertiv for you in 2026. These guys didn’t just ride the wave; they created a tsunami in the digital infrastructure sector. Net sales ballooned by a staggering 61% compared to last year's same quarter, pulling in $4.313 billion. When you consider the...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 38

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
2026 Data Integration Stars: User Sentiments Revealed

Updated Category News Views 18

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Continue Reading
Right College Fit Crucial for Graduation Rates

Updated Category News Views 60

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Continue Reading
GeoComm and Rypplzz Team Up for 3D Mapping Breakthrough

Updated Category News Views 45

Cracking the Mystery of Multilevel Locations Let me tell you, when lives hang in the balance, every second counts. We've all seen the chaos when first responders are trying to pinpoint someone's location inside a building with more floors than a loaf of bread. Enter GeoComm and Rypplzz, the new superheroes in this story. These two companies have realized the opportunity...

Continue Reading
Probiotics in Animal Feed: Market Reaches $8.76B by 2031

Updated Category News Views 14

Let's cut straight to the chase: the probiotics in animal feed market is steaming ahead, set to grow from a respectable $5.82 billion in 2026 to a hearty $8.76 billion by 2031. We're talking about a solid CAGR of 8.5% here. Now that's the kind of growth trajectory that gets even the most jaded traders sitting up and taking notice. Big Numbers in Livestock Nutrition...

Continue Reading
JELD-WEN Kicks Off 2027 Senior Notes Exchange

Updated Category News Views 22

A Fresh Play: Swapping Old for New With a fresh brew in hand and the latest company maneuvers on the table, JELD-WEN's move to exchange its 4.875% Senior Notes due 2027 for new secured notes maturing in 2031 comes into focus. This ain't just some routine shuffling of papers. They're calling up eligible folks holding onto those old notes, saying, 'Why stick with the old...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Seamless Customer Experience: Insights from Info-Tech

Updated Category News Views 159

Transforming Customer Engagement with Omnichannel Strategies In an era where digital interactions dominate, businesses are increasingly feeling the strain of disjointed customer experiences. Despite investing heavily in digital tools, many organizations find themselves navigating a labyrinth of disconnected channels, leading to frustrating customer journeys. Info-Tech...

Continue Reading
Bulat Utemuratov Foundation Provides Housing for Families in Need

Updated Category News Views 170

Bulat Utemuratov Foundation Provides Housing for Families in Need The Bulat Utemuratov Foundation has recently made a significant commitment to providing housing for families in need by donating 500 apartments to the local government of Astana. This generous contribution, valued at an impressive 10.5 billion tenge, is part of the Foundation's broader charitable initiative...

Continue Reading
Discover the Journey of a $100 Investment in AbbVie Stock

Updated Category News Views 170

The Growth of AbbVie: A Decade of Investment AbbVie (NYSE: ABBV) has shown impressive performance in the stock market, consistently outpacing market averages. Over the last decade, AbbVie has delivered an average annual return of 15.43%, exceeding general market returns by 2.87%. With a market capitalization nearing $406.27 billion, AbbVie stands as a significant player...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 122

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Experience Romer's Premier Baby Gear at Strolleria Event

Updated Category News Views 207

Join Romer for an Exclusive In-Store Event Romer, recognized for its premium baby gear designed for families, is thrilled to invite expectant parents, families, media, and influencers to an exciting event. This occasion will take place at Strolleria, a revered destination for baby products, and showcases Romer's elegant and safe gear. Details of the Event The event will...

Continue Reading